<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-75518</identifier>
<setSpec>0212-6982</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Treatment with 131I of thyroid remnants in a patient with papillary thyroid carcinoma and end-stage chronic renal failure</dc:title>
<dc:description xml:lang="en">The follow-up and treatment of thyroid cancer presents several aspects subject to discussion, such as its management in patients with End-Stage Renal Failure (ESRF). We present a patient with ESRF and papillary thyroid carcinoma, which had to be coordinated among different departments (Endocrinology, Nuclear Medicine, Nephrology and Physics and Radiation Protection). Both the diagnostic scintigraphy with 123I and the ablative treatment with 131I performed later were performed with the administration of rh TSH. The room in which the metabolic therapy was to be performed was prepared for the patient's periodic hemodialysis. The 131I dose used was 80% of the usual dose. This made it possible to assure the therapeutic effect and that the patient's stay in hospital would only be for 5 days. Throughout the whole diagnostic and therapeutic process, no adverse effects attributable to rh TSH or radioiodine were observed. The coordination among the departments involved enabled an effective and safe process for the patient</dc:description>
<dc:creator>Prats, E</dc:creator>
<dc:creator>Rivas, M. A</dc:creator>
<dc:creator>Tardín, L</dc:creator>
<dc:creator>Santapau, A</dc:creator>
<dc:creator>Camara, A</dc:creator>
<dc:creator>Andres, A</dc:creator>
<dc:creator>Álvarez, R</dc:creator>
<dc:creator>Parra, A</dc:creator>
<dc:creator>Banzo, J</dc:creator>
<dc:creator>Razola, P</dc:creator>
<dc:creator>Ruiz, P</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">El seguimiento y tratamiento del cáncer de tiroides presenta diversos aspectos para debatir, como el manejo en pacientes con insuficiencia renal crónica terminal (IRCT). Presentamos el caso de una paciente con IRCT y carcinoma papilar de tiroides, que requirió un proceso de coordinación entre diferentes servicios (Endocrinología, Medicina Nuclear, Nefrología, y Física y Protección Radiológica). Tanto la gammagrafía diagnóstica con 123I como el tratamiento ablativo con 131I posterior se realizaron con administración de hormonoterapia sustitutiva recombinante humana (TSH rh). Se acondicionó la habitación de terapia metabólica para realizar hemodiálisis periódica a la paciente. La dosis de radioyodo fue un 80% de la habitual, lo que permitió garantizar el efecto terapéutico y que el ingreso hospitalario durara únicamente 5 días. Durante todo el proceso diagnóstico y terapéutico no se observaron efectos adversos atribuibles a la TSH rh ni al radioyodo. La coordinación entre los servicios implicados permitió un proceso efectivo y seguro para la paciente(AU)</dc:description>
<dc:source>Rev Esp Med Nucl;29(1): 32-35, ene.-feb. 2010.</dc:source>
<dc:identifier>ibc-75518</dc:identifier>
<dc:title xml:lang="es">Tratamiento con 131I de restos tiroideos en paciente con carcinoma papilar de tiroides e insuficiencia renal crónica terminal</dc:title>
<dc:subject>^d50495^s22012</dc:subject>
<dc:subject>^d7621^s22073</dc:subject>
<dc:subject>^d14349^s29166</dc:subject>
<dc:subject>^d22696^s22016</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d22696^s29166</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d2334^s22016</dc:subject>
<dc:subject>^d14348^s22074</dc:subject>
<dc:subject>^d14347^s29166</dc:subject>
<dc:subject>^d14349^s22053</dc:subject>
<dc:subject>^d50495^s22016</dc:subject>
<dc:subject>^d2334^s22012</dc:subject>
<dc:type>article</dc:type>
<dc:date>201002</dc:date>
</metadata>
</record>
</ibecs-document>
